On Monday, Cutera stock received an upgrade to its Relative Strength (RS) Rating, from 89 to 96. The stock soared 30% the last two trading days on news that the U.S. Food and Drug Administration's clearance of AviClear, the first and only energy-based device for the treatment of mild, moderate, and severe acne.
When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength. This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks often have an RS Rating north of 80 in the early stages of their moves.
Looking For Winning Stocks? Try This Simple Routine
Is Cutera Stock A Buy?
Cutera stock cleared a cup without handle with a 60.45 buy point on above-average volume. Be aware that it's a third-stage base. Such patterns do sometimes lead to significant gains, but, statistically, they're more likely to fail than first- or second-stage consolidations. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The relative strength has entered new high ground, a sign the stock is outperforming the general market in terms of price performance.
The company showed -55% earnings growth in its most recent report. Revenue rose 31%.
Cutera stock earns the No. 4 rank among its peers in the Medical-Systems/Equipment industry group. Sensus Healthcare and Iradimed are among the top 5 highly rated stocks within the group.
